Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Sep 28, 2021 1:00 PM - Sep 30, 2021 5:30 PM

(Central Europe Standard Time)

Accelerating CMC Workshop

Innovation and Convergence in a post COVID-19 world

Session 6: ICH Expansion and the Journey towards Harmonisation

Session Chair(s)

Frank  Montgomery, PHD

Frank Montgomery, PHD

Global Head Regulatory CMC, GRAPSQA, AstraZeneca, United Kingdom

Susanne  Ausborn, PHD

Susanne Ausborn, PHD

Global Head International Regulatory Policy, Roche, Switzerland

The expansion of ICH brings the promise of more rapid access to medicines to a wider population of patients. It does though make the practicalities of harmonisation across a greater diversity of regulators more demanding. This is particularly the case in the CMC area where the detailed technical requirements not only impact the initial approval but ongoing future supply and accessibility for patients. This session will describe the work of the ICH members in the continued journey towards harmonisation, with some insight from newer members and an industry perspective on the continued opportunities to be tackled.

Speaker(s)

Frank  Montgomery, PHD

Frank Montgomery, PHD

Global Head Regulatory CMC, GRAPSQA, AstraZeneca, United Kingdom

IQ Survey on Control Strategy Acceptance; Opportunity for further harmonisation

Matt  Popkin, PHD

Matt Popkin, PHD

Senior Director, CMC Excellence, Global Regulatory Affairs, GSK, United Kingdom

ICH Quality Discussion Group priorities

Wassim  Nashabeh, PHD

Wassim Nashabeh, PHD

Vice President, Global Head of Technical Regulatory Policy & International Ops, Genentech, A Member of the Roche Group, United States

Perspectives on progress to harmonisation from the ICH Assembly

Raphael  Sanches Pereira

Raphael Sanches Pereira

General Manager of the Office for Medicines, ANVISA, Brazil

Reflections from ICH new Observers and Full Members

Abdullah H. AL-Hatareshah, MSC, RPH

Abdullah H. AL-Hatareshah, MSC, RPH

Executive Director for Regulatory Affairs , Saudi Food and Drug Authority, Saudi Arabia

Reflections from ICH new Observers and Full Members

Yahya I. Al-Nujaym, MBA

Yahya I. Al-Nujaym, MBA

Director for Standards, Saudi Food and Drug Authority, Saudi Arabia

Reflections from ICH new Observers and Full Members

Milton  Bonelli, DrMed

Milton Bonelli, DrMed

ICH Management Committee Member and Scientific Advice Officer, European Medicines Agency, Netherlands

Panel discussion and Q&A, with the additional participation of

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.